scPharmaceuticalsSCPH
About: scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
Employees: 96
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2,977% more call options, than puts
Call options by funds: $400K | Put options by funds: $13K
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
4% more funds holding
Funds holding: 85 [Q4 2024] → 88 (+3) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
6.11% less ownership
Funds ownership: 79.49% [Q4 2024] → 73.37% (-6.11%) [Q1 2025]
31% less capital invested
Capital invested by funds: $141M [Q4 2024] → $97M (-$43.8M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for SCPH.
Financial journalist opinion
Based on 6 articles about SCPH published over the past 30 days
